Financial Performance - The group's revenue for the nine months ended December 31, 2022, was approximately HKD 56,000,000, a decrease of 29.3% compared to HKD 79,300,000 for the same period in 2021[5] - The loss attributable to the owners of the company for the nine months ended December 31, 2022, was approximately HKD 34,400,000, compared to a loss of HKD 29,700,000 for the same period in 2021, representing a 15.4% increase in losses[5] - For the three months ended December 31, 2022, the group's revenue was HKD 14,017,000, down 47.1% from HKD 26,414,000 in the same quarter of 2021[6] - The gross profit for the nine months ended December 31, 2022, was HKD 29,590,000, a decrease of 27.3% from HKD 40,704,000 for the same period in 2021[6] - Operating loss for the nine months ended December 31, 2022, was HKD 32,367,000, compared to HKD 29,783,000 for the same period in 2021, indicating a 8.7% increase in operating losses[6] - The basic and diluted loss per share for the nine months ended December 31, 2022, was HKD 0.1089, slightly higher than HKD 0.1087 for the same period in 2021[6] - The total equity attributable to the owners of the company as of December 31, 2022, was HKD 191,371,000, down from HKD 237,946,000 as of December 31, 2021[7] Dividend Policy - The board of directors does not recommend the payment of dividends for the nine months ended December 31, 2022, consistent with the previous year[5] - The group did not recommend the payment of dividends for the nine months ended December 31, 2022, consistent with the previous year[18] Revenue Breakdown - Revenue from lending for the three months ended December 31, 2022, was HKD 3,398,000, down from HKD 8,793,000 in the same period of 2021, a decrease of 61.3%[13] - Revenue from retail and wholesale sales of grocery products, cash vouchers, and frozen foods for the three months ended December 31, 2022, was HKD 10,619,000, down from HKD 17,621,000 in the same period of 2021, a decrease of 39.4%[13] - The lending division generated approximately HKD 19,700,000 in revenue over the nine-month period, with expectations for continued stable income in the future[28] - Retail and wholesale business revenue decreased by about 32% compared to the same period in 2021, totaling approximately HKD 36,400,000, down from HKD 53,400,000[29] Product Development - The group launched a new product line for pet products, including supplements and pet food, during the nine months ended December 31, 2022[25] - The group continues to develop its own brand products to meet changing customer demands, including a new line of human health supplements named "Cordyceps 19" due to the COVID-19 pandemic[26] - The company launched new product lines in pet products and human supplements, leading to a significant increase in inventory and deposits as of December 31, 2022[30] Corporate Actions - The company completed a placement of 72,105,000 shares at a price of HKD 0.149 per share, raising approximately HKD 10,744,000, with a net amount of about HKD 9,819,000 after expenses[32] - Following the placement, the total number of shares increased from 360,539,031 to 432,644,031[33] - The company agreed to purchase 901 shares representing approximately 90.1% of a subsidiary for HKD 1,000,000, along with a subscription for 43,000,000 new shares at HKD 0.20 each, totaling HKD 8,600,000[34] - A similar agreement was made to acquire 901 shares of another subsidiary for HKD 1,000,000, with the same subscription terms for new shares[35] Shareholder Information - As of December 31, 2022, the major shareholder, Baofeng Management Limited, held approximately 41.88% of the issued share capital[37] - The chairman and executive director, Mr. Chen Ende, is the sole beneficial owner of Baofeng Management Limited[38] Compliance and Governance - The financial statements were prepared in accordance with the Hong Kong Financial Reporting Standards and GEM Listing Rules[10] - The group has adopted revised Hong Kong Financial Reporting Standards effective from April 1, 2022, with no significant impact on the financial position or performance during the reporting period[11] - The group has not provided any corporate guarantees to third parties as of December 31, 2022[22] - The company has not purchased, sold, or redeemed any of its listed securities during the nine-month period[39] - The board of directors has confirmed compliance with the trading standards throughout the nine-month period[41] - The audit committee has reviewed the unaudited consolidated performance for the nine-month period, ensuring compliance with applicable accounting standards[45] - The company has established a remuneration committee consisting of four independent non-executive directors and three executive directors to review and set remuneration policies[46] - The company has formed a nomination committee to provide recommendations on any proposed changes and the election of directors[47]
仍志集团控股(08079) - 2023 Q3 - 季度财报